Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, today announced its financial results for the first half of the year, approved by the Board of Directors at its meeting of 12 October 2016.
[button link=”http://www.quantum-genomics.com/www/wp-content/uploads/2016/10/QUANTUM_PR_H1-2016-results_20161013_EN.pdf” target=”_blank” title=”Download Press Release” size=”small” color=”red”]